Protocol Ledger

NCT06237452 · Phase III · RECRUITING

VE303 for Prevention of Recurrent Clostridioides Difficile Infection

Interventional Phase III clinical trial protocol NCT06237452 sponsored by Vedanta Biosciences in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-05-20 Enrollment: 852 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06237452
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)852 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06237452
Protocol FieldVerified Registry Value
NCT IdentifierNCT06237452
Consolidated Lead SponsorVedanta Biosciences
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment852 participants (ESTIMATED)
Registered Start Date2024-05-20
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06237452
Hospital Research SiteLocationSite Profile
Mayo Clinic ArizonaPhoenix, AZOpen Hospital Dossier ->
Children's Hospital Los AngelesLos Angeles, CAOpen Hospital Dossier ->
UCLA Health and Jonsson Comprehensive Cancer CenterLos Angeles, CAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI